HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential
TipRanksFeb 28 16:55 ET
Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside
TipRanksFeb 6 23:36 ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
TipRanksNov 28, 2023 16:40 ET
Deutsche Bank Upgrades HUTCHMED (China) to Buy, Raises Price Target to $22.1
BenzingaNov 24, 2023 05:08 ET
HUTCHMED (China) Analyst Ratings
BenzingaNov 24, 2023 04:59 ET
HUTCHMED's Global Expansion and New Product Launches Bolster Buy Rating: An Analysis of Growth Prospects and Market Potential
TipRanksNov 24, 2023 03:55 ET
HUTCHMED (China) Analyst Ratings
BenzingaNov 10, 2023 11:03 ET
Analysts Conflicted on These Healthcare Names: HUTCHMED (HCM), Bayer (OtherBAYRY) and Compass Therapeutics (CMPX)
TipRanksNov 9, 2023 09:22 ET
Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
BenzingaSep 5, 2023 09:58 ET
HUTCHMED (China) Analyst Ratings
BenzingaSep 5, 2023 09:57 ET
Bank of America Securities Sticks to Its Buy Rating for HUTCHMED (HCM)
TipRanksAug 22, 2023 06:05 ET
Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
BenzingaJul 24, 2023 09:53 ET
HUTCHMED (China) Analyst Ratings
BenzingaJul 24, 2023 09:52 ET
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), MacroGenics (MGNX) and HUTCHMED (HCM)
TipRanksAug 9, 2022 12:35 ET
Goldman Sachs Adjusts HUTCHMED (China)'s Price Target to $16 From $14, Maintains Neutral Rating
MT NewswiresAug 9, 2022 09:48 ET
HUTCHMED (China) Is Maintained at Neutral by Goldman Sachs
Dow JonesAug 9, 2022 09:02 ET
HUTCHMED (China) Price Target Raised to $16.00/Share From $14.00 by Goldman Sachs
Dow JonesAug 9, 2022 09:02 ET
HUTCHMED (China) analyst ratings
Benzinga Analyst RatingsAug 9, 2022 08:54 ET
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $16
Benzinga Real-time NewsAug 9, 2022 08:54 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teva Pharmaceutical (TEVA), HUTCHMED (HCM) and Arcutis Biotherapeutics (ARQT)
TipRanksAug 2, 2022 08:45 ET
No Data
No Data